Alterity Therapeutics (ATHE) vs Edesa Biotech (EDSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Edesa Biotech (EDSA) has outperformed Alterity Therapeutics (ATHE) over the past year, gaining 17.6% versus a loss of 56.7%. Over five years, ATHE leads with a -85.4% price change compared with -95.6% for EDSA. Alterity Therapeutics is the larger company by market cap ($29.0 million vs $27.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATHE | EDSA |
|---|---|---|
| Share price | $1.52 | $2.00 |
| Market cap | $29.02M | $27.02M |
| 1-day change | -8.16% | -8.05% |
| YTD return | -50.65% | +40.85% |
| 1-year return | -56.70% | +17.65% |
| 5-year return | -85.38% | -95.63% |
| EPS (TTM) | $-0.90 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-7.19M |
| 52-week high | $5.89 | $20.32 |
| 52-week low | $1.52 | $0.72 |
| Distance from 52-week high | -74.19% | -90.16% |
| Analyst consensus | none | none |
| Avg. price target upside | +771.71% | +716.50% |
| Average volume | 89.63K | 1.45M |
| Shares outstanding | 19.09M | 13.51M |
| Employees | 11 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed ATHE by 74.3 percentage points over the past year.
About Alterity Therapeutics
ATHE stock →Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
ATHE vs EDSA FAQ
Which is bigger, Alterity Therapeutics or Edesa Biotech?
Alterity Therapeutics (ATHE) is larger, with a market capitalization of $29.02M compared with $27.02M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, ATHE or EDSA?
EDSA returned +17.65% over the past 12 months, compared with -56.70% for ATHE (price return, excluding dividends). Past performance does not predict future results.
Are Alterity Therapeutics and Edesa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.